Comparison of Azithromycin and Co-Amoxiclav in the Treatment of Acute Tracheobronchitis and Acute Infectious Exacerbations of Chronic Bronchitis in Adults

Abstract

Azithromycin, a broad-spectrum azalide, and co-amoxiclav were compared in a randomized, multicentre, open-label trial in 759 patients treated for acute tracheobronchitis (n = 620) or acute infectious exacerbations of chronic bronchitis (n = 139). Patients were randomized (2:1) to a 3-day regimen of two azithromycin 250 mg capsules once daily or a 5–10-day regimen of co-amoxiclav, one 625 mg tablet three times daily. Azithromycin produced a significantly higher cure rate (70.6% versus 61.1%) than (P = 0.011) and there were fewer failures (7.8% versus 13.6%) and relapses in the azithromycin-treated group, giving a higher overall response rate for azithromycin (89.7% versus 80.2%, P = 0.0003). With azithromycin, compliance was better than with co-amoxiclav and there was a significantly shorter time to improvement or cure. A higher incidence of adverse events, mostly gastrointestinal, was reported by patients taking co-amoxiclav (21.3% versus 14%, P = 0.0097), causing more patients in this group to discontinue therapy (7% versus 1.2%, P = 0.00004).

Keywords

Azithromycin Co-amoxiclav Bronchitis Community-acquired infection Tolerance Compliance

Get full access to this article

View all access options for this article.

References

Moroni

Franzetti

Antinori

: Antibiotic therapy in bronchopulmonary infections. Ann Ital Med Int 1992; 7 (Suppl 3); 86S–93S.

Davies

Measen

FPV

: Treatment of Branhamella catarrhalis infections. J Antimicrob Chemother 1990; 25: 1–7.

Thorn

Grayston

Wang

: Chlamydia pneumoniae strain TWAR, Mycoplasma pneumoniae, and viral infections in acute respiratory disease in a university student health clinic population. Am J Epidemiol 1990; 132: 248–256.

Morandini

Perduca

Zannini

: Clinical efficacy of azithromycin in lower respiratory tract infections. J Chemother 1993; 5: 32–36.

Principi

Marchisio

Biasini

: Azithromycin versus erythromycin in the treatment of paediatric community-acquired pneumonia. Eur J Clin Res 1993; 4: 127–133.

Meinert

: Sample size and power estimates. In: Clinical trials: design, conduct and analysis. Monographs in epidemiology and biostatistics, 1986; 8: 71–89. Oxford University Press.

Sternon

And collaborative group: Open randomized study comparing doxycycline and co-amoxiclav in the treatment of acute suppurative tracheobronchitis in adults. J Int Med Res 1995; 23: 369–376.

Hoepelman

AIM

Sips

van Helmond

JLM

: A single-blind comparison of 3-day azithromycin and 10-day co-amoxiclav treatment of acute lower respiratory tract infections. J Antimicrob Chemother 1993; 31 (Supple E): 147–152

Bradbury

: Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. J Antimicrob Chemother 1993; 31 (Suppl. E): 153–162

10.

Dunn

Barradell

: Azithromycin–a review of its pharmacological properties and use as a 3-day therapy in respiratory tract infections. Drugs 1996; 51: 483–505.

11.

Sternon

Leclerq

Knepper

: Azithromycin compared with clarithromycin in the treatment of adult patients with acute purulent tracheobronchitis: a cost-of-illness study. J Int Med Res 1995; 23: 413–422.

12.

Baldwin

Wise

Andrews

: Azithromycin concentrations at the sites of pulmonary infection. Eur Resp J 1990; 3: 886–890.

13.

Wise

: The pharmacokinetics of azithromycin. Rev Contemp Pharmacother 1994; 5: 329–340.